Lawrence E. Leibowitz - 26 Jun 2023 Form 4 Insider Report for Enfusion, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 26 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Jun 2023, 16:15:33 UTC
Prior SEC filing: 20 Jun 2023
Next SEC filing: 10 Aug 2023
Source filing: View source filing
Reporting owner signature: /s/ Matthew Campobasso, as Attorney-in-Fact

Key filing fact

Lawrence E. Leibowitz filed Form 4 for Enfusion, Inc. on 28 Jun 2023.

Key facts

This page summarizes Lawrence E. Leibowitz's Form 4 filing for Enfusion, Inc..
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 28 Jun 2023, 16:15.

Change

Previous filing in this sequence was filed on 20 Jun 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ENFN transaction

Class A Common Stock

Award

Transaction value: $0
Shares: +15,233
Change %: +12%
Price: $0.000000
Shares after: 139,284
Date: 26 Jun 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Consists of restricted stock units ("RSUs") awarded pursuant to the Enfusion, Inc. 2021 Stock Option and Incentive Plan. The RSUs will vest in full on the earlier of June 16, 2024, or the date of the 2024 annual meeting of stockholders of the issuer.